<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837859</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-4470</org_study_id>
    <nct_id>NCT04837859</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma</brief_title>
  <acronym>INDIE</acronym>
  <official_title>Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to establish an individualized first-line treatment incorporating&#xD;
      checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Programmed cell death protein-1 (PD-1) blockade is highly effective and well tolerated in&#xD;
      relapsed or refractory cHL and has also demonstrated efficacy in the first-line treatment of&#xD;
      cHL in combination with doxorubicin, vinblastine, and dacarbazine (AVD) in the phase II GHSG&#xD;
      NIVAHL trial. A relevant proportion of patients achieved an early metabolic complete&#xD;
      remission (CR) with anti-PD-1 monotherapy and might not require standard chemo- or&#xD;
      radiotherapy. Limiting therapy-associated short- and long-term side effects of these&#xD;
      conventional treatments including impaired quality of life, second primary malignancies or&#xD;
      organ damage is of utmost importance in the predominantly young cHL patients. This trial will&#xD;
      hence further reduce treatment intensity and provide a chemo- and radiotherapy-free therapy&#xD;
      to optimally responding patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A age 18-60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients at the age of 18-60 years at enrollment will receive 2 initial doses of 200 mg tislelizumab in 21-day intervals followed by an interim positron emission tomography (PET-2). Following a PET-guided approach, patients with a negative PET-2 (i.e. Deauville score 1-3) according to central review will continue receiving tislelizumab for another 4 doses of 300 mg in 28-day intervals. Patients with a positive PET-2 (i.e. Deauville score &gt;3) will receive 4 cycles of combined 300 mg tislelizumab on day 1 and AVD chemotherapy on day 1 and 15 in 28-day cycles (4x T-AVD). For all patients, 30 Gy involved-site radiotherapy (IS-RT) will only be applied in case of PET positivity after completion of (chemo-) immunotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Age 60+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients above the age of 60 years will be enrolled in a separate, exploratory cohort and receive PET-guided treatment with tislelizumab or T-AVD as described above. However, all patients in the exploratory cohort for older patients will receive consolidating 30 Gy IS-RT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients</description>
    <arm_group_label>Arm A age 18-60</arm_group_label>
    <arm_group_label>Arm B Age 60+</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 for the main trial cohort&#xD;
&#xD;
          -  Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for&#xD;
             the exploratory cohort&#xD;
&#xD;
          -  First diagnosis of treatment-naïve cHL&#xD;
&#xD;
          -  Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d,&#xD;
             stage IIB with risk factors c-d):&#xD;
&#xD;
               1. large mediastinal mass&#xD;
&#xD;
               2. extranodal lesion(s)&#xD;
&#xD;
               3. elevated erythrocyte sedimentation rate&#xD;
&#xD;
               4. ≥ 3 nodal areas&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and/or&#xD;
             central nervous system involvement of lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Engert, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Department of Medicine, Cologne Universit Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Fuchs</last_name>
    <email>ghsg@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>1st Department of Medicine, Cologne University Hospital</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Andreas Engert</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

